Engineered Escherichia Coli for the in Situ Secretion of Therapeutic Nanobodies in the Gut

Camie LesserDr. Cammie Lesser from Massachusetts General Hospital, Harvard Medical School, will join Targeting Microbiota 2023 on October 17-19 to present her latest research "Engineered Escherichia Coli for the in Situ Secretion of Therapeutic Nanobodies in the Gut".

Dr. Lesser will elaborate on the development of PROT3EcT, a platform of commensal and probiotic E. coli outfitted with a programmable secretion system. PROT3EcT can secrete functional single-domain antibodies (nanobodies), high-specificity therapeutics, into its surroundings. TNF-PROT3EcT, a variant that secretes TNF-alpha neutralizing nanobodies is as efficacious as systematically administered anti-TNF-alpha neutralizing monoclonal antibodies in inhibiting the development of colitis in a preclinical mouse model of Inflammatory Bowel Disease. 

About Dr. Lesser

Dr. Lesser is a physician-scientist whose lab is interested in deciphering the ways that bacterial pathogens manipulate host cells to promote their own survival and dissemination. She has a long-standing interest in studying the pathogenesis of Shigella flexneri, focusing on its type III secretion system, a complex nanomachine that it uses to inject over 30 different proteins into human host cells. Projects in her lab focus on understanding how type III secreted proteins are defined as substrates, deciphering how they act to manipulate eukaryotic host cell processes, and most recently in engineering these secretion systems to develop engineered E. coli as a therapeutic protein delivery platform. 

Join Targeting Microbiota 2023 to learn more about Dr. Lesser's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website



Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next